Cystatin C as a Parameter of Glomerular Filtration Rate in Patients with Ovarian Cancer

Bodnar, Lubomir; Wcisło, Gabriel; Smoter, Marta; Gąsowska-Bodnar, Agnieszka; Stec, Rafał; Synowiec, Agnieszka; Szczylik, Cezary

doi:10.1159/000319097

Cited by 30 publications

(20 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…On the other hand, in a study regarding ovarian cancer patients who received paclitaxel-cisplatin combination, no correlation was noted between cystatin C and the other GFR markers (serum creatinine level, Cockcroft-Gault, and MDRD formulations). 24 In the same study, significant correlations were found between the cystatin C levels and pretreatment tumor dimension and also with CA 125 levels. As a cysteine protease inhibitor, cystatin C is elevated in the presence of this tumor, which might explain why the cystatin C level does not reflect GFR.…”

Section: Discussionmentioning

confidence: 78%

Evaluation of the Renal Function Using Cystatin C Level in the Patients Receiving Cisplatin-Based Chemotherapy

et al. 2013

View full text Add to dashboard Cite

Objective: There are some data regarding the role of cystatin C, a cysteine proteinase inhibitor, in determining the glomerular filtration rate (GFR) more accurately. We aimed to evaluate the correlation of serum cystatin C levels with the serum creatinine levels and GFR calculated by Cockcroft-Gault and modification of diet in renal disease (MDRD) formulations in the patients who received cisplatin-based chemotherapy. We also intended to demonstrate its potential use in the early prediction of the renal function changes in these patients. Materials and methods: In the study, 34 patients receiving cisplatin-based chemotherapy with various malignancies were included. The levels of cisplatin were determined prior to the chemotherapy and at the end of cisplatin infusion during the therapy. GFR was calculated by Cockcroft-Gault and MDRD formulations prior to the therapy and at the end of the third course. Results: A statistically significant linear correlation was found between the serum levels of cystatin C and creatinine prior to the chemotherapy (r ¼ 0.42, p ¼ 0.013). However, there was no correlation among the level of cystatin C subsequent to the cisplatin infusion and serum creatinine level following the third course and MDRD and creatinine clearance-Cockcroft-Gault formulations. Conclusion: Even though the serum cystatin C levels were correlated with the serum creatinine levels in our study, it was concluded that it was not an appropriate parameter to predict the potential impairments in the renal function during the chemotherapy.

show abstract

Section: Discussionmentioning

confidence: 78%

Evaluation of the Renal Function Using Cystatin C Level in the Patients Receiving Cisplatin-Based Chemotherapy

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Kos et al reported that serum Cys-C levels were significantly higher in patients with advanced melanoma and colorectal cancer than in patients with primary melanoma and healthy controls (11,12). Other investigators, however, reported that Cys-C is not influenced by tumor extent (13). In malignancy, an imbalance between cysteine proteases and their inhibitors, associated with metastatic tumor cell phenotype, is thought to facilitate tumor cell invasion and metastasis (27).…”

Section: Discussionmentioning

confidence: 99%

“…Singh et al reported that Cys-C concentrations have moderate associations with CRP and fibrinogen that are not dependent on CrCl (10). In addition, results of recent studies have shown a significant correlation between serum Cys-C levels and malignant progression in colorectal cancer, melanoma and ovarian cancer (11)(12)(13), although earlier studies reported that serum Cys-C levels were not affected by the presence of malignancies (14,15). With regard to serum Cys-C levels in patients with lung cancer, there is only one report by Naumnik et al (16).…”

Section: Introductionmentioning

confidence: 99%

Serum levels of cystatin C in elderly lung cancer patients

et al. 2011

View full text Add to dashboard Cite

“…In vitro , CysC secretion is not affected by cisplatin [18], but the effect of other anti-emetics on CysC production or release is unknown. In vitro , CysC transcription is increased in numerous cancer cell lines [38, 39], and in some patients with malignancy there is increased pCysC [40, 41], which has generally correlated with burden of disease [42, 43]. …”

Section: Discussionmentioning

confidence: 99%

Dexamethasone Modifies Cystatin C-Based Diagnosis of Acute Kidney Injury During Cisplatin-Based Chemotherapy

Pianta

Pickering

Succar

et al. 2017

Kidney Blood Press Res

View full text Add to dashboard Cite

Background/Aims: Plasma cystatin C (pCysC) may be superior to serum creatinine (sCr) as a surrogate of GFR. However, the performance of pCysC for diagnosing acute kidney injury (AKI) after cisplatin-based chemotherapy is potentially affected by accompanying corticosteroid anti-emetic therapy and hydration. Methods: In a prospective observational study pCysC, sCr, urinary kidney injury molecule-1 (KIM-1), and urinary clusterin were measured over 2 weeks in 27 patients given first-cycle chemotherapy. The same variables were measured over 2 weeks in Sprague–Dawley rats given a single intraperitoneal injection of dexamethasone, cisplatin, or both, and in controls. Results: In patients, pCysC increases were greater than sCr 41% vs. 16%, mean paired difference 25% (95% CI: 16–34%)], relative increases were ≥ 50% in 9 patients (35%) for pCysC compared with 2 (8%) for sCr (p = 0.04) and increases in sCr were accompanied by increased KIM-1 and clusterin excretion, but increases in pCysC alone were not. In rats, dexamethasone administration produced dose-dependent increases in pCysC (and augmented cisplatin-induced increases in pCysC), but did not augment histological injury, increases in sCr, or KIM-1 and clusterin excretion. Conclusions: In the presence of dexamethasone, elevation of pCysC does not reliably diagnose AKI after cisplatin-based chemotherapy.

show abstract

Cystatin C as a Parameter of Glomerular Filtration Rate in Patients with Ovarian Cancer

Cited by 30 publications

References 42 publications

Evaluation of the Renal Function Using Cystatin C Level in the Patients Receiving Cisplatin-Based Chemotherapy

Evaluation of the Renal Function Using Cystatin C Level in the Patients Receiving Cisplatin-Based Chemotherapy

Serum levels of cystatin C in elderly lung cancer patients

Dexamethasone Modifies Cystatin C-Based Diagnosis of Acute Kidney Injury During Cisplatin-Based Chemotherapy

Contact Info

Product

Resources

About